Bicara Therapeutics Inc. ...

AI Score

XX

Unlock

15.65
0.14 (0.90%)
At close: Apr 24, 2025, 3:59 PM
15.43
-1.44%
Pre-market: Apr 25, 2025, 07:10 AM EDT

Bicara Therapeutics Common Stock Statistics

Share Statistics

Bicara Therapeutics Common Stock has 54.52M shares outstanding. The number of shares has increased by null% in one year.

Shares Outstanding 54.52M
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Institutions (%) 85.26%
Shares Floating -
Failed to Deliver (FTD) Shares 2.16K
FTD / Avg. Volume 0.4%

Short Selling Information

Short Interest n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Valuation Ratios

The PE ratio is -43.05 and the forward PE ratio is -4.93. Bicara Therapeutics Common Stock's PEG ratio is 0.72.

PE Ratio -43.05
Forward PE -4.93
PS Ratio 0
Forward PS 4.2
PB Ratio 5.95
P/FCF Ratio -39.13
PEG Ratio 0.72
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Bicara Therapeutics Common Stock.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 27.93, with a Debt / Equity ratio of 0.

Current Ratio 27.93
Quick Ratio 27.93
Debt / Equity 0
Debt / EBITDA -0.01
Debt / FCF -0.01
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $0
Profits Per Employee $-1.24M
Employee Count 55
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax -187K
Effective Tax Rate 0.28%

Stock Price Statistics

The stock price has increased by null% in the last 52 weeks. The beta is -1.41, so Bicara Therapeutics Common Stock's price volatility has been lower than the market average.

Beta -1.41
52-Week Price Change null%
50-Day Moving Average 12.92
200-Day Moving Average null
Relative Strength Index (RSI) 68.07
Average Volume (20 Days) 539.32K

Income Statement

Revenue n/a
Gross Profit 0
Operating Income -82.39M
Net Income -68M
EBITDA -82.39M
EBIT n/a
Earnings Per Share (EPS) -0.4
Full Income Statement

Balance Sheet

The company has 489.71M in cash and 738K in debt, giving a net cash position of 488.97M.

Cash & Cash Equivalents 489.71M
Total Debt 738K
Net Cash 488.97M
Retained Earnings -221.02M
Total Assets 510M
Working Capital 484.54M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -74.75M and capital expenditures -71K, giving a free cash flow of -74.82M.

Operating Cash Flow -74.75M
Capital Expenditures -71K
Free Cash Flow -74.82M
FCF Per Share -0.45
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

BCAX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for BCAX is $33, which is 110.9% higher than the current price. The consensus rating is "Buy".

Price Target $33
Price Target Difference 110.9%
Analyst Consensus Buy
Analyst Count 7
Stock Forecasts

Scores

Altman Z-Score 24.95
Piotroski F-Score 1